Oncology
Our discovery approach is based on three steps:
- Select biologically validated targets linked to high unmet medical needs, with a clear line of sight to clinical success, where we believe there is an opportunity to apply our drug discovery capabilities;
- Apply Redx’s molecule design framework, leveraging our strength and experience in medicinal chemistry to optimise a best in class molecule for the target;
- Deliver high quality targeted small molecules with a clear line of sight to the clinic.
In addition to our wholly-owned undisclosed in-house research programmes, we have a research collaboration with Jazz Pharmaceuticals covering two targets on the Ras/RAF/MAPK pathway.
Collaboration showcase: In September 2020 Redx announced a new research collaboration with Jazz Pharmaceuticals
The 2020 collaboration recognises our expertise in oncology drug design following previous sale of our Pan-RAF inhibitor programme to Jazz in July 2019 and builds on this success with a second major partnership. In this collaboration, Redx will lead discovery and preclinical development activities on two targeted cancer therapies on the Ras/RAF/MAP kinase pathway. Redx received an initial $10 million on signing and is eligible for a further $10 million in year 2 of discovery, with up to a further $400 million in milestone payments, plus tiered royalties should the programmes be successful in generating a molecule.
Read the press releaseWe are excited to collaborate with Redx on two oncology programs in the Ras/Raf/MAP kinase pathway. Redx has established itself as a strong partner for Jazz, given the continued momentum in our existing collaboration on pan-RAF, and we look forward to this new collaboration and access to Redx’s small molecule discovery capabilities.